ASCO 2019: Abstract Recommendations From Dr. Wafiq El-Deiry for Colorectal Cancer
gives a synopsis of some recent papers being presented at ASCO.
direct links can also be accessed by visiting this page :
https://www.practiceupdate.com/expertopinion/4096/2/1?elsca1=emc_enews_daily-digestSession: Gastrointestinal (Colorectal) Cancer
Monday June 3, 2019; 8:00 AM–11:00 AM
3514 A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC). AR Parikh, JW Clark, JY-L Wo, et al
3528 Genomic alterations after EGFR blockade in patients with RAS wild-type metastatic colorectal cancer: Combined tissue and blood-based analysis from SCRUM-Japan GI-SCREEN and GOZILA. Y Nakamura, R Yamashita, W Okamoto, et al
3551 Modulation of autophagy: A phase II study of vorinostat (VOR) plus hydroxychloroquine (HCQ) vs regorafenib (RGF) in chemo-refractory metastatic colorectal cancer (mCRC). SP Arora, LL Tenner, J Sarantopoulos, et al
3565 Survival according to mutations in BRAF, KRAS, or microsatellite instability (MSI-H) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases from colorectal cancer. SG Larsen, S Dueland, M Goscinski, et al
Publication Only
e15020 A phase Ib trial to evaluate the safety and efficacy of quinacrine plus capecitabine in patients with refractory metastatic colorectal cancer. A Winer, N Vijayvergia, SJ Cohen, et al
e15054 A phase I clinical trial of fluorouracil (5-FU) + devimistat (CPI-613) combination in previously treated patients (pts) with metastatic colorectal cancer (MCR). CMSPR Lima, AT Alistar, RJ Desnoyers, et al